Osteoporosis: Economic Burden of Disease in Italy
- PMID: 32248346
- DOI: 10.1007/s40261-020-00904-8
Osteoporosis: Economic Burden of Disease in Italy
Abstract
Background and objective: Today, osteoporosis is the most common bone disease and an important public health problem in all developed countries. The objective of this study was to estimate the costs associated with the management and treatment of osteoporosis in order to assess the economic burden in Italy for 2017, in terms of direct medical costs and social security costs.
Methods: A cost of illness model was developed to estimate the average cost per year sustained by the NHS (National Health Service) and Social Security System in Italy. A systematic literature review was performed to obtain epidemiological, direct and indirect costs parameters where available. Hospitalisation costs were calculated considering the administrative database of the hospital discharge records for the period 2008-2016. Patients were enrolled in the analysis if they report the subsequent inclusion criteria: age ≥ 45 years and presence of osteoporosis in primary or secondary diagnosis (ICD9-CM 733.0) and/or presence of a major fracture in primary or secondary diagnosis (excluding road accidents) in the following locations: spine (codes ICD9-CM: 805;806), femur (codes ICD9-CM: 820; 821), radius and ulna (codes ICD9-CM: 813.4; 813.5), humerus (codes ICD9-CM: 812.0-812.5), pelvis (code ICD9-CM: 808), tibia and fibula (codes ICD9-CM: 823), ankle (code ICD9: 824) and ribs (codes ICD9-CM: 807.0; 807.1). Costs were estimated considering the diagnosis-related group (DRG) national tariff associated with each hospitalisation. Finally, the administrative databases of the Italian National Social Security Institute (INPS) (2009-2015) were analysed for the estimate the pension and disability costs from the social perspective.
Results: The model estimated an average annual economic burden of osteoporosis in Italy of €2.2 billion. Of this cost, approximately 80% (€1.8 billion) was associated with hospitalisations, 16% (€351 million) for pharmacological treatments, 3% (€71 million) for ambulatory visits, and 0.6% (€13 million) for social security costs. The average yearly cost per patient was equal to €8691 (€8591 for hospitalisations). Analysing severe patients, hospitalisation costs increase to €12,336 (+ 44% if compared to non-severe osteoporosis patients).
Conclusions: The analysis showed that osteoporosis represents one of the main health problems in Italy and the ability to maintain patients in a non-severe health state could decrease the economic burden from both NHS and social perspective.
Similar articles
-
An Analysis of the Social and Economic Costs of Breast Cancer in Italy.Int J Environ Res Public Health. 2021 Aug 26;18(17):9005. doi: 10.3390/ijerph18179005. Int J Environ Res Public Health. 2021. PMID: 34501588 Free PMC article.
-
Economic Impact of Schizophrenia from a Hospital and Social Security System Perspective in Italy.Clin Drug Investig. 2021 Feb;41(2):183-191. doi: 10.1007/s40261-020-00991-7. Epub 2021 Feb 9. Clin Drug Investig. 2021. PMID: 33559103
-
The short-term economic burden of gestational diabetes mellitus in Italy.BMC Pregnancy Childbirth. 2018 Feb 23;18(1):58. doi: 10.1186/s12884-018-1689-1. BMC Pregnancy Childbirth. 2018. PMID: 29471802 Free PMC article.
-
Epidemiology and economic burden of osteoporosis in Switzerland.Arch Osteoporos. 2014;9:187. doi: 10.1007/s11657-014-0187-y. Epub 2014 Jun 27. Arch Osteoporos. 2014. PMID: 24970672 Review.
-
The burden of osteoporosis in four Latin American countries: Brazil, Mexico, Colombia, and Argentina.J Med Econ. 2019 Jul;22(7):638-644. doi: 10.1080/13696998.2019.1590843. Epub 2019 Mar 25. J Med Econ. 2019. PMID: 30835577 Review.
Cited by
-
An Analysis of the Social and Economic Costs of Breast Cancer in Italy.Int J Environ Res Public Health. 2021 Aug 26;18(17):9005. doi: 10.3390/ijerph18179005. Int J Environ Res Public Health. 2021. PMID: 34501588 Free PMC article.
-
Prevalence and patterns of anti-osteoporotic drug use based on 2019 real-world nationwide data in Greece.Arch Osteoporos. 2022 Jun 28;17(1):86. doi: 10.1007/s11657-022-01126-5. Arch Osteoporos. 2022. PMID: 35761110
-
Bone Mineral Density Reference Values in 18- to 95-Year-Old Population in Lombardy Region, Italy.Am J Mens Health. 2022 Sep-Oct;16(5):15579883221119363. doi: 10.1177/15579883221119363. Am J Mens Health. 2022. PMID: 36305327 Free PMC article.
-
Dalbavancin Efficacy and Impact on Hospital Length-of-Stay and Treatment Costs in Different Gram-Positive Bacterial Infections.Clin Drug Investig. 2021 May;41(5):437-448. doi: 10.1007/s40261-021-01028-3. Epub 2021 Apr 21. Clin Drug Investig. 2021. PMID: 33884583 Free PMC article.
-
Associations of LRP5 Gene With Bone Mineral Density, Bone Turnover Markers, and Fractures in the Elderly With Osteoporosis.Front Endocrinol (Lausanne). 2020 Sep 25;11:571549. doi: 10.3389/fendo.2020.571549. eCollection 2020. Front Endocrinol (Lausanne). 2020. PMID: 33101205 Free PMC article.
References
MeSH terms
LinkOut - more resources
Full Text Sources
Medical